Trial Profile
Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2019
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms LEVALS
- Sponsors Orion
- 09 Dec 2019 According to an Orion media release, data from this trial was presented at the 30th International Symposium on ALS/MND in Perth, Australia last week
- 02 Dec 2019 According to a Orion media release, biomarker and pharmacokinetic data from this trial will be presented at the 30th International Symposium on ALS/MND held on 4-6 December 2019 in Perth, Australia.
- 26 Oct 2017 Status changed from active, no longer recruiting to completed, according to an Orion media release.